HomeCompareCYDX vs EPRT

CYDX vs EPRT: Dividend Comparison 2026

CYDX yields 319.49% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYDX wins by $2321.74M in total portfolio value
10 years
CYDX
CYDX
● Live price
319.49%
Share price
$0.63
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2321.80M
Annual income
$1,437,007,509.12
Full CYDX calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — CYDX vs EPRT

📍 CYDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYDXEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYDX + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYDX pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYDX
Annual income on $10K today (after 15% tax)
$27,156.55/yr
After 10yr DRIP, annual income (after tax)
$1,221,456,382.75/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, CYDX beats the other by $1,221,445,187.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYDX + EPRT for your $10,000?

CYDX: 50%EPRT: 50%
100% EPRT50/50100% CYDX
Portfolio after 10yr
$1160.93M
Annual income
$718,510,339.99/yr
Blended yield
61.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CYDX
No analyst data
Altman Z
-915.4
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYDX buys
0
EPRT buys
0
No recent congressional trades found for CYDX or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYDXEPRT
Forward yield319.49%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$2321.80M$64.3K
Annual income after 10y$1,437,007,509.12$13,170.85
Total dividends collected$2234.83M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CYDX vs EPRT ($10,000, DRIP)

YearCYDX PortfolioCYDX Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$42,649$31,948.88$11,212$512.01+$31.4KCYDX
2$172,979$127,344.31$12,689$692.09+$160.3KCYDX
3$667,791$482,703.57$14,521$944.30+$653.3KCYDX
4$2,456,121$1,741,585.04$16,841$1,302.88+$2.44MCYDX
5$8,614,513$5,986,463.27$19,841$1,821.64+$8.59MCYDX
6$28,840,623$19,623,094.50$23,818$2,587.47+$28.82MCYDX
7$92,257,949$61,398,482.44$29,230$3,744.65+$92.23MCYDX
8$282,273,878$183,557,872.52$36,816$5,540.38+$282.24MCYDX
9$826,908,344$524,875,294.32$47,806$8,413.17+$826.86MCYDX
10$2,321,799,437$1,437,007,509.12$64,324$13,170.85+$2321.74MCYDX

CYDX vs EPRT: Complete Analysis 2026

CYDXStock

CYduct Diagnostics, Inc., a healthcare instrument company, develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of disease and medical conditions. The company's products include breast endoscopy systems; 3-chip and 1-chip camera systems; cameras and accessories; endoscopic instruments, such as dissectors, graspers, scissors, needle holders, fan retractors, cautery instruments, and insufflation needles; and illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps. It also offers insufflators; laparoscopic instruments, such as general surgery, lymphadenectomy, gynecology, and thorascopy instruments; rigid scopes and accessories, including laparoscopes, operative scopes, cystoscopes, and scope trays; trocar and cannula sets, cannulas, trocars, reducer sleeves, and seals; video carts; instrument handles that include insulated handles and non-insulated handles; and veterinary instrumentation. The company was formerly known as Solos Endoscopy, Inc. and changed its name to CYduct Diagnostics, Inc. in December 2020. CYduct Diagnostics, Inc. was founded in 1986 and is based in Westport, Connecticut.

Full CYDX Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CYDX vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYDX vs SCHDCYDX vs JEPICYDX vs OCYDX vs KOCYDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.